Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 113B 98.02B 90.35B 84.66B 158B 10,815B 161B 1,078B 417B 5,213B 424B 415B 18,127B P/E Ratio 2026 *
25.4x
P/E Ratio 2027 * 22.6x
Enterprise Value 100B 86.93B 80.13B 75.08B 140B 9,591B 143B 956B 370B 4,623B 376B 368B 16,075B EV / Sales 2026 *
7.68x
EV / Sales 2027 * 6.72x
Free-Float
99.8%
Yield 2026 *
-
Yield 2027 * -
1 day+2.14%
1 week+0.75%
Current month-0.56%
1 month+2.27%
3 months-9.61%
6 months-0.20%
Current year-1.84%
1 week 433.8
Extreme 433.8
449.5
1 month 420.01
Extreme 420.01
456.68
Current year 412.27
Extreme 412.27
507.92
1 year 362.5
Extreme 362.5
507.92
3 years 335.82
Extreme 335.82
519.88
5 years 176.36
Extreme 176.36
519.88
10 years 71.46
Extreme 71.46
519.88
Manager TitleAgeSince
Chief Executive Officer 53 31/03/2020
Director of Finance/CFO 58 09/04/2019
Chief Tech/Sci/R&D Officer - 30/06/2021
Director TitleAgeSince
Director/Board Member 66 31/12/1997
Chairman 70 30/04/2012
Director/Board Member 57 17/06/2015
Date Insider Type Main position Quantity % Market Cap.
06-04Sell

Chief Technology Officer

-1,745 0.0007%
05-31Sell

General Counsel

-828 0.0003%
05-28Sell

Chief Technology Officer

-1,974 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+2.14%+0.75%-1.64%+33.20% 111B
+2.16%+3.17%+43.57%+160.28% 1,013B
-0.07%+4.45%+53.50%+48.95% 574B
-0.08%-0.08%+17.37%+62.66% 397B
+0.77%+4.97%+21.24%+15.95% 324B
+0.85%+2.79%+24.89%+15.93% 280B
+2.10%+7.06%+24.57%+34.79% 273B
+4.84%+2.45%+21.33%+61.85% 182B
-0.19%+3.96%-45.64%-48.23% 194B
+3.61%-2.56%+15.16%+61.12% 151B
Average +1.61%+2.55%+17.44%+44.65% 349.92B
Weighted average by Cap. +1.37%+3.92%+28.42%+71.26%

Financials

2026 *2027 *
Net sales 13.04B 11.31B 10.43B 9.77B 18.26B 1,248B 18.64B 124B 48.17B 602B 48.94B 47.89B 2,092B 14.27B 12.38B 11.41B 10.69B 19.98B 1,366B 20.4B 136B 52.71B 658B 53.56B 52.4B 2,290B
Net income 4.45B 3.86B 3.56B 3.34B 6.23B 426B 6.36B 42.47B 16.44B 205B 16.71B 16.35B 714B 5.05B 4.39B 4.04B 3.79B 7.08B 484B 7.22B 48.22B 18.67B 233B 18.97B 18.56B 811B
Net Debt -12.78B -11.09B -10.23B -9.58B -17.9B -1,224B -18.28B -122B -47.23B -590B -47.99B -46.96B -2,052B -17.13B -14.87B -13.71B -12.84B -24B -1,641B -24.5B -163B -63.3B -791B -64.32B -62.94B -2,750B
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
11/06/26 445.04 $ +2.14% 1,233,857
10/06/26 435.71 $ -2.26% 1,103,240
09/06/26 445.77 $ +0.63% 871,497
08/06/26 442.96 $ -0.87% 1,149,408
05/06/26 446.83 $ +1.15% 1,530,180
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
445.04USD
Average target price
548.69USD
Spread / Average Target
+23.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!